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A B S T R A C T
Background
Long-acting beta2-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic
obstructive pulmonary disease. These interventions are often taken together in a combination inhaler. However, the relative added
value of the two individual components is unclear.
Objectives
To determine the relative effects of inhaled corticosteroids (ICS) compared to long-acting beta2-agonists (LABA) on clinical outcomes
in patients with stable chronic obstructive pulmonary disease.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials (latest search August 2011) and reference lists of articles.
Selection criteria
We included randomised controlled trials comparing inhaled corticosteroids and long-acting beta2-agonists in the treatment of patients
with stable chronic obstructive pulmonary disease.
Data collection and analysis
Three authors independently assessed trials for inclusion and then extracted data on trial quality, study outcomes and adverse events.
We also contacted study authors for additional information.
Main results
We identified seven randomised trials (5997 participants) of good quality with a duration of six months to three years. All of the trials
compared ICS/LABA combination inhalers with LABA and ICS as individual components. Four of these trials included fluticasone and
salmeterolmonocomponents and the remaining three included budesonide and formoterolmonocomponents. There was no statistically
significant difference in our primary outcome, the number of patients experiencing exacerbations (odds ratio (OR) 1.22; 95% CI 0.89
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to 1.67), or the rate of exacerbations per patient year (rate ratio (RR) 0.96; 95% CI 0.89 to 1.02) between inhaled corticosteroids and
long-acting beta2-agonists. The incidence of pneumonia, our co-primary outcome, was significantly higher among patients on inhaled
corticosteroids than on long-acting beta2-agonists whether classified as an adverse event (OR 1.38; 95% CI 1.10 to 1.73) or serious
adverse event (Peto OR 1.48; 95% CI 1.13 to 1.93). Results of the secondary outcomes analysis were as follows. Mortality was higher in
patients on inhaled corticosteroids compared to patients on long-acting beta2-agonists (Peto OR 1.17; 95% CI 0.97 to 1.42), although
the difference was not statistically significant. Patients treated with beta2-agonists showed greater improvements in pre-bronchodilator
FEV1 compared to those treated with inhaled corticosteroids (mean difference (MD) 18.99 mL; 95% CI 0.52 to 37.46), whilst greater
improvements in health-related quality of life were observed in patients receiving inhaled corticosteroids compared to those receiving
long-acting beta2-agonists (St George’s Respiratory Questionnaire (SGRQ) MD -0.74; 95% CI -1.42 to -0.06). In both cases the
differences were statistically significant but rather small in magnitude. There were no statistically significant differences between ICS
and LABA in the number of hospitalisations due to exacerbations, number of mild exacerbations, peak expiratory flow, dyspnoea,
symptoms scores, use of rescue medication, adverse events, all cause hospitalisations, or withdrawals from studies.
Authors’ conclusions
Placebo-controlled trials have established the benefits of both long-acting beta-agonist and inhaled corticosteroid therapy for COPD
patients as individual therapies. This review, which included trials allowing comparisons between LABA and ICS, has shown that the
two therapies confer similar benefits across the majority of outcomes, including the frequency of exacerbations and mortality. Use of
long-acting beta-agonists appears to confer a small additional benefit in terms of improvements in lung function compared to inhaled
corticosteroids. On the other hand, inhaled corticosteroid therapy shows a small advantage over long-acting beta-agonist therapy in
terms of health-related quality of life, but inhaled corticosteroids also increase the risk of pneumonia. This review supports current
guidelines advocating long-acting beta-agonists as frontline therapy for COPD, with regular inhaled corticosteroid therapy as an adjunct
in patients experiencing frequent exacerbations.
P L A I N L A N G U A G E S U M M A R Y
Comparing inhaled corticosteroids with long-acting beta2-agonists in treating chronic obstructive pulmonary disease (COPD)
Inhalers containing corticosteroids, long-acting beta2-agonists or both can be used to treat severe chronic obstructive pulmonary disease
(COPD). However, the benefits and harms of the two individual treatments are unclear when comparing one treatment with the other.
We looked at clinical trials that compared the two kinds of inhalers to find the effects of each on health and well-being in patients
with COPD. We found seven studies (involving 5997 participants) comparing the long-term benefits and side effects of inhaled
corticosteroids and long-acting beta2-agonists for treating COPD. Overall, we found no significant difference between the two drugs
in the number of people having an exacerbation (worsening of COPD symptoms). More people taking inhaled corticosteroids suffered
episodes of pneumonia compared to people using long-acting beta2-agonists, although pneumonia was extremely rare in both groups.
Inhaled corticosteroids do not improve lung function as much as long-acting beta2-agonists but did improve patients’ quality of life
more than long-acting beta2-agonists. The differences in lung function and quality of life were rather small.
B A C K G R O U N D
The Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines for the treatment of patients with chronic ob-
structive pulmonary disease (COPD) state that beta2-agonists are
a central therapy for the alleviation of symptoms (GOLD 2010).
Inhaled long-acting beta2-agonists (LABAs) improve lung func-
tion (Boyd 1997) and health-related quality of life (Jones 1997)
and are recommendedby currentNational Institute forHealth and
Clinical Excellence (NICE) guidelines in the treatment of COPD
(NICE 2010). A Cochrane review of the efficacy of LABA in peo-
ple with stable COPD reported significant benefits on a range of
outcomes including improved lung function, improved health-re-
lated quality of life and fewer exacerbations of COPD, confirming
LABA as an effective therapy in COPD (Appleton 2006).
Long-term treatment with inhaled corticosteroids (ICS) has not
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been found to modify the rate of decline in forced expiratory vol-
ume in one second (FEV1) (Pauwels 1999; Vestbo 1999; Burge
2000; Lung Health 2000) but, in moderate or severe COPD, ICS
has been shown to reduce the frequency and severity of exacerba-
tions (Burge 2000). Both the GOLD and NICE guidelines rec-
ommend the addition of regular treatment with inhaled corticos-
teroids to bronchodilator treatment for patients with an FEV1 <
50% predicted who are symptomatic or suffer repeated exacer-
bations of COPD (GOLD 2010; NICE 2010). Treatment with
inhaled corticosteroids has also been shown to reduce the rate
of deterioration in health-related quality of life (Spencer 2001)
through a reduction in exacerbation frequency (Spencer 2003).
A Cochrane review of ICS for stable COPD reported a range of
therapeutic benefits including improved lung function, improved
health-related quality of life and fewer exacerbations of COPD,
with no associated impact on mortality rates compared to placebo
(Yang 2007).
This evidence for the effectiveness of LABA and ICS for COPD
has led to the development of combination therapies that con-
tain both an inhaled corticosteroid and a long-acting beta2-ago-
nist (Calverley 2003 a). However, the relative benefits of LABA
and ICS in the treatment of COPD has not been fully explored.
Recent findings from clinical trials suggest that the impact of com-
bination therapies on a range of outcomes may not be a simple
additive effect, for example in the comparisons of combination
versus monocomponents (ICS or LABA) for exacerbation rates
(Calverley 2003 a; Calverley 2007). This makes an investigation
of the relative added value of LABAs compared to ICS even more
important. Of particular concern is the relative impact of the treat-
ments on adverse outcomes such as mortality.
The aim of this review is to evaluate the relative added value of
inhaled corticosteroids compared to long-acting beta2-agonists on
clinical endpoints.
O B J E C T I V E S
To determine the relative effects of inhaled corticosteroids and
long-acting beta2-agonists on clinical endpoints in patients with
stable COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published and unpublished randomised trials (RCTs)
that included comparisons between inhaled corticosteroids and
long-acting beta2-agonists in the treatment of patients with stable
COPD.
Types of participants
We included patients with a clinical diagnosis of COPD, and not
asthma, that fulfilled any of the following internationally recog-
nised diagnostic guidelines: American Thoracic Society (ATS),
European Respiratory Society (ERS) and Global Initiative for
Chronic Obstructive Lung Disease (GOLD). We only included
studies with patients who were clinically stable at study entry, as
defined by an exacerbation-free study run-in period, and that had
excluded patients with significant comorbidity.
Types of interventions
We included regular inhaled corticosteroids comparedwith regular
inhaled long-acting beta2-agonists administered by any inhalation
device. We included the following inhaled corticosteroid versus
inhaled long-acting beta2-agonist comparisons.
1.1. Formoterol versus beclomethasone
1.2. Formoterol versus budesonide
1.3. Formoterol versus ciclesonide
1.4. Formoterol versus fluticasone
1.5. Formoterol versus mometasone
1.6. Formoterol versus triamcinolone
2.1. Salmeterol versus beclomethasone
2.2. Salmeterol versus budesonide
2.3. Salmeterol versus ciclesonide
2.4. Salmeterol versus fluticasone
2.5. Salmeterol versus mometasone
2.6. Salmeterol versus triamcinolone
We allowed long-acting anticholinergics, for example tiotropium,
as co-interventions.
Types of outcome measures
Primary outcomes
1. Moderate or severe exacerbations: defined as those requiring
treatment with antibiotics or oral corticosteroids, or both,
expressed as the total number of exacerbations
2. Hospitalisations due to exacerbations
3. Pneumonia
Secondary outcomes
1. All cause mortality
2. Mild exacerbations: defined as a worsening of symptoms
not necessitating treatment with antibiotics or oral
corticosteroids, expressed as the total number of exacerbations
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3. Change in forced expiratory volume in 1 second (FEV1)
and other measures of pulmonary function
4. Quality of life scales
5. Symptom scores of breathlessness and other symptom scores
6. Inhaled rescue medication use during the treatment period
7. Adverse events
8. All cause hospitalisations
9. Withdrawal from study
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Group Specialised Register for
randomised controlled trials. The Register is derived from system-
atic searches of bibliographic databases including the Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane
Library), MEDLINE, EMBASE and CINAHL, and handsearch-
ing of respiratory journals and meeting abstracts (please see the
Airways Group search methods for further details). All records in
the Register coded as ’COPD’ were searched using the following
strategy:
((bronchodilator* AND long*) OR ((beta* AND agonist*) AND
long-acting OR “long acting”) OR ((beta* AND adrenergic*)
AND long-acting OR “long acting”) OR salmeterol OR Serevent
OR formoterol OR Foradil OR Oxis OR eformoterol OR
fenoterol OR bambuterol OR Bambec) AND ((*steroid OR
steroid* OR corticosteroid* OR corticoid* OR glucocorticoid*
OR “adrenal cortex hormones”)OR (fluticasoneORFlixotideOR
beclomethasone OR beclometasone OR QVAR OR budesonide
OR Pulmicort OR mometasone OR Asmanex OR triamcinolone
ORKenalogOR ciclesonide ORAlvesco ORCIC OR flunisolide
OR Aerobid)).
Searching other resources
We checked the reference lists of all included randomised con-
trolled trials and review articles for additional references. We con-
tacted authors of identified randomised trials about other pub-
lished and unpublished studies.
Data collection and analysis
Selection of studies
Two of us (SS and DJE) independently assessed the titles and
abstracts of all retrieved trials. Using the full text of each study,
we independently selected trials for inclusion in the review. We
resolved disagreements about relevance by consensus.
Data extraction and management
Three of us (SS, DJE and CK) independently extracted data from
the included studies and the data were then aggregated. We sought
data missing from the publications through correspondence with
the study authors. We extracted variance data from all arms of
the included studies to enable calculation of the variance of the
ICS versus LABA difference, where this was not reported. We
combined data from all trials using RevMan 5.
Assessment of risk of bias in included studies
We assessed the risk of bias for all included studies according to
recommendations outlined in theCochrane Handbook of Systematic
Reviews of Interventions (Higgins 2008) for the following items.
1. Allocation sequence generation.
2. Concealment of allocation.
3. Blinding of participants and investigators.
4. Incomplete outcome data.
5. Selective outcome reporting.
We graded each potential source of bias as either low, high or
unclear. We noted other sources of bias.
Measures of treatment effect
We summarised proportional outcomes, such as the proportion
who improved, using an odds ratio (OR) with a fixed-effect Man-
tel-Haenszel model, unless zero cells were present in which case we
used Peto odds ratios. We analysed continuous data as weighted
mean difference (MD) with a fixed-effect model. In trials where
individual group datawere not reported and treatment effects were
only given as differences between treatment groups, we analysed
data using the generic inverse variance (GIV) functionwith a fixed-
effect model. A number of trials reported the difference between
ICS and LABA arms but did not report the appropriate variance
around this difference. In this case, we calculated the variance of
the difference between ICS and LABA using the variances of all
the trial arms, see Appendix 1. We did not impute variances from
other studies in any of the analyses in this review.
Dealing with missing data
We contacted investigators and manufacturers of the preparations
for missing data, where necessary.
Assessment of heterogeneity
We performed tests for heterogeneity using the I2 statistic in
RevMan 5. Where I2 was greater than 20% we also conducted a
sensitivity analysis by pooling data with a random-effects model
and comparing this to the results of the fixed-effect model.
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Assessment of reporting biases
We planned to inspect funnel plots for signs of publication bias.
Subgroup analysis and investigation of heterogeneity
We pooled the analysis across studies but performed subgroup
analyses for each corticosteroid versus beta2-agonist comparison.
The treatment periods were stratified into less than one year, and
more than one year. We pooled studies with different doses of the
same inhaled corticosteroid and planned to carry out subgroup
testing to compare different doses, when the data allowed this.
Sensitivity analysis
Weplanned to carry out sensitivity analysis based on study quality.
R E S U L T S
Description of studies
Results of the search
The electronic search returned 431 references. From these, we
identified 115 as potentially relevant. After further assessment we
found that 99 references belonging to seven studies were eligible
and 16 references were excluded with reasons given. The latest
search was run in August 2011.
Included studies
Full details of all included studies can be found in the
Characteristics of included studies table.
Study design
All the included studies were multi-centre, randomised, double-
blind, placebo-controlled with a parallel-group design. TORCH
2007 was the longest trial with a treatment duration of three years.
Calverley 2003, Szafranski 2003 and TRISTAN 2003 were one-
year studies, and Hanania 2003, Mahler 2002 and Tashkin 2008
had a duration of six months.
Sample size
The studies included 5997 participants of which 2991 were ran-
domised to LABA treatment and 3006 to ICS treatment. TORCH
2007 was the largest study with 3093 participants. The other stud-
ies had between 300 to 800 participants each.
Participants
The mean age of participants was 64 years. The average gender
distribution varied from 62% males in Hanania 2003 to 78%
in Szafranski 2003. All participants were diagnosed with COPD
according to GOLD 2010, ATS or ERS classifications. Disease
severity in the included studies ranged from moderate to very
severe COPD. The average baseline lung function varied from 1.0
to 1.3 L for FEV1, and from 36% to 45% for FEV1 predicted,
across the studies.
Interventions
In Calverley 2003, Szafranski 2003, and Tashkin 2008 the LABA
used was formoterol at 4.5 µg, two inhalations twice daily; and
the ICS was budesonide, two inhalations twice daily at 200, 200
and 160 µg, respectively. Hanania 2003, Mahler 2002, TORCH
2007 and TRISTAN 2003 looked at the LABA salmeterol and the
ICS fluticasone. Salmeterol was used at a dose of 50 µg twice daily
and the ICS fluticasone at 500 µg twice daily. The exception was
Hanania 2003, which used fluticasone at a dose of 250 µg twice
daily.
Permitted co-treatment
All included studies allowed reliever medication, such as terbu-
taline or salbutamol, when necessary to relieve symptoms. In the
majority of studies tiotropium was not a permitted co-treatment.
Calverley 2003 also allowed courses of oral corticosteroids (maxi-
mum three weeks per course) and antibiotics in the event of exacer-
bations, and parenteral steroids or nebulised treatment (single in-
jections or inhalations), or both, at emergency visits. Tashkin 2008
allowed oral and parenteral corticosteroids (not depot formula-
tions), acute use of xanthines, increased use of inhaled beta-adreno-
ceptor agonists and ipratropium bromide, nebulized beta-adreno-
ceptor agonists and ipratropium bromide. TORCH 2007 allowed
patients to continue any medication for COPD other than cor-
ticosteroids and inhaled long-acting bronchodilators. TRISTAN
2003 allowed regular treatment with anticholinergics, mucolytics
and theophylline. All non-COPD medications could be contin-
ued if the dose remained constant, whenever possible, and if their
use would not be expected to affect lung function.
Outcomes
All the included studies looked at COPD exacerbations, FEV1,
health-related quality of life and adverse events.Most of the studies
also recorded symptoms, use of reliever medication, dyspnoea and
peak expiratory flow (PEF).
Excluded studies
Fourteen references from 11 studies were excluded as they failed
to meet the eligibility criteria for the review (see Characteristics
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of excluded studies). Nine of these did not include trial arms of
monotreatmentwith inhaled corticosteroid and long-acting beta2 -
agonist (DellaCioppa 2001; Cazzola 2003; Barnes 2005; Gosman
2006; Jiang 2009; Nungtjik 2009;Worth 2009;Mittmann 2010).
The remaining two references were reviews (Lyseng-Williamson
2002; Reynolds 2004).
Risk of bias in included studies
An assessment of the risk of bias for each study is presented in the
Characteristics of included studies, and an overview of the findings
is shown in Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each ’Risk of bias’ item for each included
study.
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Allocation
Szafranski 2003, Tashkin 2008, TORCH 2007 and TRISTAN
2003 reported using computer-generated randomisation sched-
ules for list generation and were therefore judged to be at low risk
of bias. Patients who met the inclusion criteria were assigned the
next consecutive treatment number from the generated list. In-
formation regarding sequence generation for the other included
studies, and details of allocation concealment procedures for all
included studies (except TORCH 2007), were not reported and
these were judged to be at unclear risk of bias. In TORCH 2007
the principal investigators were provided with the participant’s
treatment number as well as a treatment pack number through an
automated 24-hour telephone number. For all other studies there
were insufficient descriptions of allocation concealment methods
to allow judgement of anything other than unclear risk of bias
against this criterion.
Blinding
All the included studies were double-blind, though only Szafranski
2003, Tashkin 2008, TORCH 2007 and TRISTAN 2003 gave
details of the blinding of participants and clinicians, permitting a
judgement of low risk of bias. In Szafranski 2003 all the inhalers
were identical to ensure that the patients, pharmacists and the
investigators were blinded to the allocated treatment. In Tashkin
2008 patients received both a pressurizedmetered-dose inhaler and
a dry powder inhaler containing either active treatment or placebo,
or combinations of active treatment and placebo, as appropriate.
In TORCH2007 andTRISTAN 2003 study drugs were packaged
in identical inhaler devices to ensure that both the patients and
investigators were unaware of treatment allocation.
Incomplete outcome data
All included studies had substantial withdrawal rates (20% to
40%). However, the rates were broadly comparable in the ICS
and LABA treatment groups with the exception of Mahler 2002,
where there was a notable difference between ICS (40%) and
LABA (28%) dropout rates. Most of the studies, including
Mahler 2002, described intention-to-treat data analyses, though
TRISTAN 2003 did not state whether follow-up data were col-
lected for discontinued patients.
Selective reporting
All included trials adequately reported the outcome data specified
in the published methods and were therefore judged to be at low
risk of bias for this criterion.
Effects of interventions
Please note that a number of trials reported the difference between
ICS and LABA arms but did not report the appropriate variance
around this difference. In these cases we calculated the variance of
the difference between ICS and LABA using the variances of all
the trial arms, see Appendix 1. Variances were not imputed from
other studies in any of the analyses in this review.
Inhaled corticosteroid versus long-acting beta2-
agonist
Primary outcome: exacerbations
Four studies (4750 participants) reported exacerbation rate ratios
between ICS or LABA and placebo or a ICS/LABA combina-
tion (Calverley 2003; Szafranski 2003; TRISTAN 2003; TORCH
2007). Analysis of the rate ratio (RR) between ICS and LABA
was not statistically significant (RR 0.96; 95% confidence interval
(CI) 0.89 to 1.02) (Analysis 1.1), and the CI was narrow enough
to exclude large differences between the two treatments, see Figure
2. There was no evidence of a class effect when comparing the
fluticasone/salmeterol trials to the budesonide/formoterol trials in
a subgroup analysis (Chi2 = 1.57, df = 1, P = 0.21). There was
no statistically significant difference in exacerbation RR between
studies of ≤ 1 year and > 1 year of treatment (Chi2 = 0.11, df = 1,
P = 0.75), see Figure 3. Tashkin 2008 was excluded from the anal-
ysis because CIs, P values or standard deviations were not reported
for any of the rate ratio comparisons. Two studies comparing flu-
ticasone versus salmeterol reported the number of patients expe-
riencing exacerbations requiring either treatment with antibiotics
or corticosteroids, or both, or hospitalisation during the treatment
period (Mahler 2002; Hanania 2003) (688 participants, Analysis
1.2). In these studies, although more patients on ICS (136/351)
suffered exacerbations than on LABA (115/337), the CIs were
wide and there was no statistically significant difference between
the groups (OR 1.22; 95% CI 0.89 to 1.67).
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Figure 2. Forest plot of comparison: 1 Inhaled corticosteroids versus long-acting beta2-agonists by ICS and
LABA, outcome: 1.1 Exacerbation rate ratios.
Figure 3. Forest plot of comparison: 2 Inhaled corticosteroids versus long-acting beta2-agonists by length of
study, outcome: 2.1 Exacerbation rate ratios.
Primary outcome: hospitalisations due to exacerbations
Exacerbations leading to hospitalisations were only reported in a
single trial (TORCH 2007) with 3093 participants. A comparison
of rate ratios showed there was no significant difference in the
risk of hospitalisation due to exacerbation between fluticasone and
salmeterol (RR 1.07; 95% CI 0.91 to 1.26) (Analysis 1.3).
Primary outcome: pneumonia
Three studies (4164 participants) reported the number of pa-
tients suffering from episodes of pneumonia as adverse events
(Calverley 2003; TORCH 2007; Tashkin 2008). The three-year
study, TORCH 2007 (3093 participants), showed a significantly
higher incidence of pneumonia in patients on fluticasone com-
pared to patients on salmeterol (OR 1.43; 95% CI 1.13 to
1.81). The other two shorter studies (Tashkin 2008: six months,
Calverley 2003: 1 year), comparing budesonide/formoterol, had
few events and wide CIs and showed no statistically significant
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difference between the treatment groups (OR 0.84; 95% CI 0.36
to 1.96), see Figure 4. There was no significant difference between
the results of TORCH 2007 and the other two studies (Chi2 =
1.43, df = 1, P = 0.23). Overall there was an increased risk of pneu-
monia on ICS compared to LABA (OR 1.38; 95% CI 1.10 to
1.73) as shown in Figure 4. This result is also shown as a Cates plot
in Figure 5, which demonstrates that for every 100 people treated
over 2.4 years, there would be seven pneumonia cases if they were
all given LABA and nine pneumonia cases if they were all given
ICS. These calculations are based on the assumption that, in such
a hypothetical situation, the patients were not also receiving the
other treatment.
Figure 4. Forest plot of comparison: 1 Inhaled corticosteroids versus long-acting beta2-agonists by ICS and
LABA, outcome: 1.4 Pneumonia adverse event.
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Figure 5. On LABA 7 people out of 100 had pneumonia (adverse event) over 2.4 years, compared to 9 (95%
CI 8 to 12) out of 100 for the ICS group. The NNT(H) for one extra person to suffer pneumonia on ICS was 42
(95% CI: 155 to 23).
Five of the included studies (5086 participants) classified pneu-
monia as a serious adverse event (Mahler 2002; Hanania 2003;
TRISTAN 2003; TORCH 2007; Tashkin 2008). A separate anal-
ysis was conducted for these studies as the distinction between ad-
verse event and serious adverse event classification of pneumonia
was unclear. Of these studies, four compared fluticasone versus
salmeterol and one compared budesonide versus formoterol. The
pooled result was again dominated by TORCH 2007 and showed
a significantly greater risk of pneumonia for patients on ICS com-
pared to patients on LABA (Peto OR 1.48; 95% CI 1.13 to 1.93),
see Figure 6. There was no statistically significant difference in
pneumonia, classified as a serious adverse event, between studies
of ≤ 1 year and > 1 year of treatment (Chi2 = 0.71, df = 1, P
= 0.40), or between the studies using fluticasone/salmeterol and
budesonide/formoterol (Chi2 = 0.42, df = 1, P = 0.51).
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Figure 6. Forest plot of comparison: 1 Inhaled corticosteroids versus long-acting beta2-agonists by ICS and
LABA, outcome: 1.5 Pneumonia serious adverse event.
Secondary outcome: mortality
All the included studies (5997 participants in seven studies) re-
ported the number of deaths from any cause during the treatment
period. The three-year TORCH 2007 study was the only one to
report mortality status for all randomised participants, including
study withdrawals. The number of events was generally low ex-
cept for TORCH 2007, which reported significantly more deaths
among patients treated with fluticasone compared to salmeterol
(Peto OR 1.23; 95% CI 1.01 to 1.50). The pooled result showed
that there was no statistically significant difference between ICS
and LABA on mortality (Peto OR 1.17; 95% CI 0.97 to 1.42; I2
= 37%), see Analysis 1.9. Since I2 was greater than 20% we per-
formed sensitivity analysis using the random-effects model (OR
0.98; 95% CI 0.59 to 1.64); this model gives much less weight
to TORCH 2007, which explains the reversal of direction of the
treatment effect. There was heterogeneity between the two sub-
groups of fluticasone versus salmeterol and budesonide versus for-
moterol (I2 = 73%) but the difference was not statistically signifi-
cant (Chi2 = 3.64, df = 1, P = 0.06).
Secondary outcome: mild exacerbations
Data on mild exacerbations not necessitating treatment with an-
tibiotics or oral corticosteroids were only reported by Hanania
2003 and Mahler 2002 (688 participants). There was no statisti-
cally significant difference between the fluticasone and salmeterol
treatment groups, though the number of occurrences was low,
leading to wide CIs (OR 1.51; 95% CI 0.74 to 3.08; I2 = 57%).
Because of heterogeneity between the studies we performed sensi-
tivity analysis using the random-effects model (OR 1.63; 95% CI
0.49 to 5.39).
Secondary outcome: measures of pulmonary function
Forced expiratory volume in one second (FEV1)
Four studies including 1993 participants reported changes in
pre-dose FEV1 (Mahler 2002; Hanania 2003; TRISTAN 2003;
Tashkin 2008). TORCH 2007 was excluded from this analysis
as the pre-bronchodilator FEV1 was not reported. The combined
result showed a smaller increase in FEV1 for ICS than LABA when
analysed with a fixed-effect model (MD -18.99; 95%CI -37.46 to
-0.52; I2 = 24%). However, since I2 was greater than 20% between
the studies we performed a sensitivity analysis. When analysed
with a random-effects model the difference in increase in FEV1
was not statistically significant (MD -17.36; 95% CI -39.54 to
4.82). There was moderate heterogeneity between the subgroups,
fluticasone versus salmeterol and budesonide versus formoterol (I
2 = 48%), but this was not statistically significant (Chi2 = 1.92, df
= 1, P = 0.17), see Analysis 1.6.
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There were also two studies (3652 participants) which reported
changes in post-dose FEV1 (TORCH2007; Tashkin 2008). There
was substantial heterogeneity between the results of the two studies
(I2 = 98%). TORCH 2007 showed no statistically significant dif-
ference in mean change in 30 minute post-bronchodilator FEV1
between fluticasone and salmeterol after three years of treatment
(MD 5mL; 95% CI -11.46 to 21.46). Tashkin 2008 on the other
hand showed a significantly smaller improvement in 60 minute
post-bronchodilator FEV1 with budesonide than with formoterol
after six months of treatment (MD -140 mL; 95% CI -177.24 to
-102.76). Because of the many substantial differences between the
two studies, the results were not pooled.
Peak expiratory flow (PEF)
Tashkin 2008 (559 participants) reported the difference in change
in morning PEF between formoterol and budesonide that was not
statistically significant (MD -4.26L/min; 95% CI -9.26 to 0.74).
Secondary outcome: quality of life
We could extract data on changes in health-related quality of life
from three studies involving 4398 participants that used the St
George’s Respiratory Questionnaire (SGRQ) (TRISTAN 2003;
TORCH 2007; Tashkin 2008). Patients treated with ICS showed
greater improvements in quality of life compared to those treated
with LABA (MD -0.74; 95% CI -1.42 to -0.06). This difference
was small in relation to the threshold of four units for a clinically
significant difference. There was no heterogeneity between the
subgroups, see Analysis 1.10.
Secondary outcome: symptom scores of breathlessness and
other symptom scores
Dyspnoea
Data on changes in dyspnoea could be extracted from five of the
included studies. Changes in dyspnoea over the treatment period
were measured using either a 0 to 4 point validated dyspnoea scale
(Calverley 2003; TRISTAN 2003; Tashkin 2008) in 2505 partic-
ipants or the validated Transition Dyspnoea Index (TDI) (Mahler
2002; Hanania 2003) in 688 participants. On the TDI scale a
higher score represents an improvement in perceived breathless-
ness, and on the 0 to 4 dyspnoea scale a higher score represents
more breathlessness. There was no statistically significant differ-
ence (MD 0.03; 95% CI -0.02 to 0.08) between ICS and LABA
using the 0 to 4 point dyspnoea scale and although there was het-
erogeneity between the two subgroups (fluticasone versus salme-
terol and budesonide versus formoterol) (I2 = 57%), this was not
statistically significant (Chi2 = 2.31, df = 1, P = 0.13) see Analy-
sis 1.11. However, there was also moderate heterogeneity among
the studies comparing budesonide and formoterol (I2 = 30%) and
among all the included studies (I2 = 47%). There was no statis-
tically significant difference between fluticasone and salmeterol
treatment in studies using the TDI (Mahler 2002; Hanania 2003)
in 688 participants (MD 0.26; 95% CI -0.21 to 0.74). CIs for the
comparisons were wide using either dyspnoea scale.
Symptoms
Symptom score data could be extracted from three studies includ-
ing 1470 participants (Calverley 2003; Szafranski 2003; Tashkin
2008). Themean improvement in symptom score was greater with
LABA than ICS (MD 0.21; 95% CI 0.06 to 0.37) although there
was no coherent pattern between the studies resulting in consider-
able heterogeneity (I2 = 62%). When analysed with a random-ef-
fects model there was no statistically significant difference between
ICS and LABA treatment (MD 0.22; 95% CI -0.03 to 0.47).
Secondary outcome: rescue medication
Tashkin 2008 (559 participants) reported a statistically significant
difference in the use of rescue medication during the treatment
period that favoured formoterol (MD 0.56 puffs/24 h; 95% CI
0.10 to 1.02).
Secondary outcome: adverse events
All adverse events
The number of patients suffering adverse events could be ex-
tracted from five studies including 5086 participants (Mahler
2002; Hanania 2003; TRISTAN 2003; TORCH 2007; Tashkin
2008). Patients receiving ICS had more adverse events (2122/
2552) compared to those receiving LABA (2070/2537), but the
difference was not statistically significant (OR 1.12; 95% CI 0.96
to 1.30). There was no heterogeneity between the subgroups.
Serious adverse events (non-fatal)
Data on the number of non-fatal, serious adverse events could
be obtained from three of the included studies (Calverley 2003;
Szafranski 2003; Tashkin 2008) (1470 participants). These three
studies all compared the risk of serious adverse events associated
with budesonide treatment versus formoterol, which was not sta-
tistically significant (OR 1.01; 95% CI 0.77 to 1.31). Data on
the number of participants experiencing one or more non-fatal,
serious adverse events were obtained from a further three of the
included studies (Mahler 2002; Hanania 2003; TRISTAN 2003)
(1434 participants). These studies all compared fluticasone versus
salmeterol. There was considerable heterogeneity among the stud-
ies (I2 = 54%), and there was no statistically significant difference
between the treatments (OR 0.93; 95% CI 0.67 to 1.31). This
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was consistent when analysed with a random-effects model (OR
1.17; 95% CI 0.60 to 2.28) (Analysis 1.15).
Secondary outcome: all cause hospitalisations
None of the included studies reported the number of patients
admitted to hospital for any cause.
Secondary outcome: withdrawals
All seven of the included studies reported the number of partici-
pant withdrawals from each treatment arm. Overall there was no
statistically significant difference in the number of withdrawals
between patients on ICS and LABA (OR 1.02; 95% CI 0.92 to
1.14; I2 = 29%) (Analysis 1.16). Subgroup analysis showed no
statistically significant differences between fluticasone versus sal-
meterol (OR 1.05; 95% CI 0.92 to 1.18) and budesonide versus
formoterol (OR 0.96; 95% CI 0.76 to 1.20). However, there was
moderate heterogeneity among the studies comparing fluticasone
and salmeterol (I2 = 58%).
D I S C U S S I O N
Summary of main results
This systematic review set out to investigate the relative effects of
inhaled corticosteroids and long-acting beta2-agonists on clinical
endpoints in patients with stable COPD using direct comparisons
from randomised trials. Seven randomised, active-control, double-
blind trials involving 5997 participants were identified. The results
of the review were dominated by the largest study, TORCH 2007,
for many outcomes (exacerbations, pneumonia, mortality, health-
related quality of life and withdrawals).
The review showed no statistically significant differences between
ICS and LABA in the number of patients experiencing exacer-
bations or the number of exacerbation per patient year (rate ra-
tio). This result was accompanied by narrow confidence intervals,
which suggests that there may not be a big difference in exacer-
bation rates between ICS and LABA. Given the pharmacologi-
cal differences between the drugs, it seems reasonable to conclude
that they are exerting different benefits (albeit of seemingly equal
clinical importance) and this endorses the assumption that ex-
acerbations are complex in terms of their pathophysiology. Data
on exacerbations leading to hospitalisation were only reported by
TORCH 2007 and also showed no statistically significant differ-
ence between ICS and LABA. Exacerbation rates are often higher
in patients who withdraw from a study before completion (Keene
2008) and this could suggest that the rates used in this review
underestimate population exacerbation frequencies. However, this
would only represent potential analytical bias in the presence of
differential dropout rates, and this study has shown parity between
ICS and LABA withdrawals.
The risk of pneumonia was significantly greater for patients on
ICS than patients on LABA, whether classified as an adverse event
(OR 1.38; 95% CI 1.10 to 1.73) or a serious adverse event (Peto
OR 1.48; 95%CI 1.13 to 1.94). The increased incidence of pneu-
monia with ICS compared to LABA appears independent of study
length. However, it should be noted that event rates were very low
(3% or less) in all studies with the exception of TORCH 2007,
the largest and longest of all the included studies.
Differences in mortality between ICS and LABA were not statisti-
cally significant (Peto OR 1.17; 95% CI 0.97 to 1.42). However,
TORCH 2007 was the only study to recordmortality status for all
randomised participants, including withdrawals, and it recorded
significantly more deaths on the ICS fluticasone compared to the
LABA salmeterol (OR 1.23; 95% CI 1.01 to 1.50). It should be
noted that very low event rates in the majority of studies may be
due, in part, to follow-up limited to patients remaining in the
study, and the study duration. Conversely, interpretation of mor-
tality data is complicated by the tendency for patients who with-
draw to then be given the other active study therapies, for exam-
ple patients withdrawing from the LABA arm are prescribed ICS,
though this is likely to reduce differences between groups rather
than to enhance them.
Treatment with ICS led to a smaller improvement in lung func-
tion (pre-bronchodilator FEV1) compared to LABA, although the
difference was relatively small (MD -18.99 mL; 95% CI -37.46
to -0.52). Post-dose FEV1 was reported in two studies and gave
very different results with high heterogeneity, and there were too
many differences between the studies to be able to pool the out-
come. The change in health-related quality of life was also signifi-
cantly different between the treatment arms but with this outcome
improvements were greater with ICS treatment than with LABA
(SGRQ MD -0.74; 95% CI -1.42 to -0.06). However, the dif-
ferences in health-related quality of life were small in comparison
to the threshold for a clinically important difference (defined as
a change of four units). Improvements in quality of life in favour
of ICS may support the idea that the drug exerts its benefits not
just in terms of alleviating or abrogating lung function impair-
ment (noting that LABA also improves lung function). Given the
possibility that COPD is a systemic disease, it may be that drug
effects on airways inflammation have wider consequences, that
is reductions in systemic consequences of airways inflammation.
There were no significant differences for hospitalisations due to
exacerbations, mild exacerbations, peak expiratory flow, dyspnoea,
symptoms scores, rescue medication, adverse events, all cause hos-
pitalisations, and withdrawals from studies.
Overall completeness and applicability of
evidence
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• This review has provided evidence to suggest that
differences in exacerbation rates between COPD patients treated
with ICS and those treated with LABA are unlikely.
• High withdrawal rates compared to low mortality rates
introduces considerable uncertainty in the analysis of mortality
from the smaller, shorter studies. However, TORCH 2007,
which was the only study with complete mortality data, reported
higher mortality with ICS therapy compared to LABA therapy.
• The size and length of TORCH 2007 lends substantial
weight to evidence for an increased risk of pneumonia with ICS
treatment compared to LABA treatment. However, event rates
across the remaining studies were low and the results should
therefore be interpreted with caution.
• The indirect comparisons between the trials comparing
budesonide with formoterol and fluticasone with salmeterol do
not allow any conclusions to be drawn about the relative efficacy
and safety of budesonide and fluticasone or formoterol and
salmeterol.
• Data synthesis was limited by the lack of common data for
several outcomes. The definition of change and impact differed
substantially with studies using: a) different outcome measures,
e.g. pre-bronchodilator or post-bronchodilator FEV1, b)
different units of analysis, e.g. mL or % change from baseline, c)
no exact measures of variability for differences between
treatments, e.g. no CI, no exact P value.
Quality of the evidence
The included studies were generally of good quality, free from se-
lective reporting of results, and all but one of the studies used in-
tention-to-treat data analysis to control for the relatively highwith-
drawal rates, which are common in long (≥ six-month) COPD
trials. However, because of the high number of withdrawals in the
included studies, the results for the dichotomous outcomes with
relatively few events (such as mortality, pneumonia and serious ad-
verse events) are less reliable when the withdrawals have not been
followed up, and must be interpreted with caution.
Potential biases in the review process
Several of the studies did not report on the statistical variance
of the difference between the ICS and LABA arms as these were
not the primary issues in those studies. We were able to calculate
these variances from exact P values or confidence intervals (see
Appendix 1). However, for some of the outcomes several studies
only provided approximate P values (see Table 1) and as we were
not able to obtain further information from the authors data for
these outcomes could not be used in this review.
Agreements and disagreements with other
studies or reviews
Several systematic reviews have tried to clarify the contribution
of ICS and LABA to the benefits and risks of the combination
inhalers in COPD. Treatment with ICS and LABA combination
inhalers has been shown to significantly reduce exacerbation rates
in COPD patients compared to placebo (rate ratio 0.74; 95% CI
0.7 to 0.8) (Nannini 2007a). In comparison to placebo, combina-
tion therapy also significantly reduced all cause mortality (primar-
ily based on TORCH 2007) (OR 0.79; 95% CI, 0.65 to 0.96);
improved health-related quality of life, symptoms and lung func-
tion; but increased the risk of pneumonia (OR 1.83; 95% CI
1.51 to 2.21) (Nannini 2007a). Systematic reviews comparing ICS
treatment with placebo have shown that ICS reduced the occur-
rence of exacerbations (risk ratio (RR) 0.82; 95%CI 0.73 to 0.92)
(Agarwal 2010), slowed the decline in health-related quality of
life (MD -1.22 units/year; 95% CI -1.83 to -0.60) and improved
FEV1 after two to six months of treatment (Yang 2007). Although
long-term use of ICS (longer than six months) did not reduce
the rate of decline in FEV1 (MD 5.80 mL/year with ICS; 95%
CI -0.28 to 11.88), it was not associated with a higher mortality
rate compared to placebo (OR 0.98; 95% CI 0.83 to 1.16) (Yang
2007). Neither of these reviews looked at adverse events, includ-
ing pneumonia. Compared to placebo, LABA treatment has also
been shown to reduce exacerbations (RR 0.78; 95% CI 0.67 to
0.91) and improve health-related quality of life (MD -3.26; 95%
CI -4.57 to -1.96) without a significant effect on mortality (RR
0.95; 95% CI 0.80 to 1.14) (Appleton 2006; Rodrigo 2008). The
reviews of placebo-controlled studies have shown benefits for both
monotherapies without an increased risk of mortality. Comparing
the effects of combination inhaler to those of its components has
shown that all cause mortality is lower with combined treatment
than with ICS alone (OR 0.77; 95% CI 0.63 to 0.94) (Nannini
2007), whereas there was no significant difference in mortality be-
tween combined inhalers and LABA alone (RR 0.90; 95%CI 0.76
to 1.06) (Nannini 2007b; Rodrigo 2009). Quality of life and lung
function favour combination treatment over both monotherapies
(Nannini 2007; Nannini 2007b; Rodrigo 2009). Combination
therapy also significantly reduced exacerbation rates compared to
the individual monotherapies: ICS/LABA versus ICS (rate ratio
0.91; 95% CI 0.85 to 0.97) (Nannini 2007), ICS/LABA versus
LABA (rate ratio 0.82; 95% CI 0.78 to 0.88) (Nannini 2007b).
A recent review found that combination inhalers did not signifi-
cantly decrease the number of severe exacerbations (RR 0.91; 95%
CI 0.82 to 1.01) but did decrease the number of moderate exacer-
bations (RR 0.84; 95% CI 0.74 to 0.96) (Rodrigo 2009). No sta-
tistically significant difference in the odds of pneumonia has been
shown between combination inhaler and ICS alone (OR 1.13;
95%CI 0.92 to 1.38) (Nannini 2007), whereas pneumonia occurs
more commonly with combined inhalers than with LABA alone
(OR 1.58; 95% CI 1.32 to 1.88 (Nannini 2007b); RR 1.63; 95%
CI 1.35 to 1.98 (Rodrigo 2009)). A recent meta analysis including
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24 randomised trials (16 fluticasone trials, seven budesonide trials
and one mometasone trial) showed a significantly increased risk of
pneumonia with ICS (RR 1.56; 95%CI 1.40 to 1.74; P = 0.0001)
(Singh 2010). The elevated risk remained consistent irrespective
of whether the ICS/LABA combination inhaler was compared to
LABA or ICS to placebo (Singh 2010).
In summary:
• both ICS and LABA may contribute to a decrease in
exacerbation rates but according to the results from this review
there is not a large difference between them;
• although ICS therapy benefits COPD patients, it also
increases the risk of pneumonia;
• the effect of ICS and LABA on mortality is more
complicated. According to Yang 2007 and Rodrigo 2008 there is
not enough evidence to say that ICS or LABA influences all
cause mortality on its own. However, in combination they seem
to cause a reduction in mortality both compared to placebo
(Nannini 2007a) and to ICS alone (Nannini 2007) but not
compared to LABA (Nannini 2007b; Rodrigo 2009). This
review supports the view that there is insufficient evidence for
the impact of LABA and ICS on mortality and the differential
impact of ICS and LABA on mortality remains unclear. Our
review showed no overall difference in mortality rates between
the monotherapies but the study with the most reliable mortality
data (TORCH 2007) showed lower rates for patients receiving
LABA therapy;
• according to this review LABA therapy is associated with
small improvements in FEV1 compared to ICS, which is
consistent with the results from the above reviews; and
• both ICS and LABA increase the patient’s quality of life but
ICS therapy is associated with slightly larger improvements.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The benefits of ICS therapy for COPD patients may be similar to
those of LABA, but there is potentially an increased incidence of
pneumonia. These data support both national and international
guidelines stating that the choice of drugs should take into account
the person’s symptomatic response, the drug’s potential to reduce
exacerbations and side effects (GOLD 2010; NICE 2010).
Implications for research
Additional work is required in assessing the risks and benefits of
budesonide/formoterol combination inhalers. Potential class ef-
fects between fluticasone and budesonide are still unknown as are
the influence of high and low doses on benefits and risks for both
drugs. The lack of key standardised outcomes is an impediment
to the synthesis of trial data for systematic reviews. We strongly
recommend international consensus on the identification and def-
inition of key common outcomes, for example change from base-
line in pre-bronchodilator FEV1 (mL), change from baseline in
health-related quality of life, and complete mortality data for all
randomised participants including study withdrawals.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Calverley 2003
Methods Design: a multi-centre, randomised, double-blind, parallel-group, placebo-controlled
study. Trial duration was 2 week run-in period followed by 52 weeks treatment. The trial
included 109 centres in 15 countries
Participants Participants: 512 patients were randomised (budesonide 257; formoterol 255)
Baseline characteristics: mean age 64 years; 74% male; mean FEV1 1.0 L; mean FEV1
predicted 36%; mean SGRQ 48
Inclusion criteria:GOLDdefinedCOPD (stages III and IV);≥ 40 years; COPD symp-
toms > 2 years; smoking history ≥ 10 pack years; FEV1/FVC ≤ 70% pre-bronchodila-
tor; FEV1 ≤ 50% predicted; use of short acting beta2-agonists as reliever medication; ≥
1 COPD exacerbation requiring oral corticosteroids/antibiotics 2 to 12 months before
first clinic visit
Exclusion criteria: history of asthma/rhinitis before 40 years of age; any relevant cardio-
vascular disorders; exacerbation of COPD requiring medical intervention within 4weeks
of run-in/during run-in phase; non-allowed medications: oxygen therapy; ICS (aside
from study medication), disodium cromoglycate, leukotriene-antagonists, 5-lipoxyge-
nase inhibitors, bronchodilators (other than study medication and terbutaline 0.5 mg as
needed), antihistamines, medication containing ephedrine, β-blocking agents
Interventions Run-in: all participants received 30 mg oral prednisolone twice daily and 2 x 4.5 mg
formoterol twice daily (2 weeks)
1. budesonide 800 µg per day: 2 x 200 µg twice daily
2. formoterol 18 µg per day: 2 x 4.5 µg twice daily
Inhaler device: Turbuhaler
Co-treatment: terbutaline 0.5 mg as needed, courses of oral corticosteroids (maximum
3 weeks per course) and antibiotics in the event of exacerbations, parenteral steroids and/
or nebulised treatment (single injections/inhalations) at emergency visits
The following medications were disallowed from recruitment: inhaled steroids (except
the studymedication), disodiumcromoglycate, leukotriene antagonists or 5-lipoxygenase
(5-LO) inhibitors, bronchodilators (other than study medication and terbutaline 0.5
mg as needed), antihistamines, any medication containing ephedrine, and β-blockers,
including eye-drops
The following medications were withheld prior to recruitment: short-acting inhaled or
oral β2-agonists (6 h before), inhaled or oral long-acting β2-agonists (48 h), inhaled
short-acting anticholinergics (8 h), inhaled long-acting anticholinergics (7 days), xan-
thine-containing derivatives (48 h), xanthine-containing derivatives (24 h), leukotriene
antagonists or 5-LO inhibitors (48 h)
Outcomes Number of exacerbations; time to first exacerbation; time to and number of oral corti-
costeroid-treated episodes; change in post-dose FEV1; slow VC; morning and evening
PEF; quality of life (SGRQ), symptoms, use of reliever medication, adverse events
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Calverley 2003 (Continued)
Notes P values used to calculate pooled SEMs for the following outcomes: Health-related
quality of life; FEV1; rescue medication
Exacerbations defined as requiring medical intervention (oral antibiotics and/or corti-
costeroids or hospitalisation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were 40% in the
inhaled corticosteroid (budesonide) group
and 44% in the long-acting beta2-agonist
(formoterol) group. However an intention-
to-treat analysis was used
Selective reporting (reporting bias) Low risk All collected data reported
Hanania 2003
Methods Design: a multi-centre, randomised, double-blind, placebo-controlled, parallel-group
study from November 1998 to August 2000. Trial duration was 2 week run-in period
followed by 24 weeks treatment. The trial included 76 hospitals in the USA. Random-
ization was stratified by reversibility and investigative site
Participants Participants: 360 patients were randomised (salmeterol 177; fluticasone 183)
Baseline characteristics: mean age 64 years; 62% male; mean FEV1 1.3 L; mean FEV1
predicted 42%; mean reversibility (FEV1% predicted) was 8.8% increase in non-re-
versible patients
Inclusion criteria: stable COPD, FEV1 40 to 65% predicted, FEV1/FVC < 70% pre-
dicted, symptoms of chronic bronchitis and moderate dyspnoea
Exclusion criteria: current diagnosis of asthma, use of oral steroids in past 6 weeks,
abnormal ECG, long-term oxygen therapy, moderate - severe exacerbation in run-in,
other significant medical disorder
Interventions Run-in: 2 weeks treatment with placebo inhaler and short acting beta2-agonist as needed
1. salmeterol 100 µg per day: 50 µg twice daily
2. fluticasone propionate 500 µg per day: 250 µg twice daily
Inhaler device: Diskus
Co-treatment: Patients were given as-needed albuterol
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Hanania 2003 (Continued)
Outcomes Exacerbations; change in pre-dose and 2 h post-dose FEV1 from baseline to end of
study. PEF data not stratified by reversibility; morning PEF; Quality of life: (CRDQ,
CBSQ not stratified by reversibility); dyspnoea (BDI, TDI); symptoms; use of reliever
medication (salbutamol); adverse events
Notes Reversibility was defined as a ≥ 12% and 200 mL increase in FEV1 from baseline
following the administration of 400 µg albuterol
Change in FEV1: mean group SE estimated from reversibility stratified SEs, then used
to calculate SD
Exacerbations were defined by treatment: moderate exacerbations requiring treatment
with antibiotics and/or corticosteroids, and severe exacerbations requiring hospitalisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk In order to account for patientwithdrawals,
endpoint was used as the primary time
point and was defined as the last on-treat-
ment post-baseline assessment excluding
any data from the discontinuation visit
Selective reporting (reporting bias) Low risk All collected data reported
Mahler 2002
Methods Design: a randomised, double-blind, placebo-controlled, parallel-group study. Trial du-
ration was 2 week run-in period followed by 24 weeks treatment. The trial included 65
centres in the USA. Randomisation was stratified by reversibility and investigative site
Participants Participants: 328 patients were randomised (salmeterol 160; fluticasone 168)
Baseline characteristics: mean age 63 years; 63% male; mean predose FEV1 1.2 L;
mean FEV1 predicted 40%
Inclusion criteria: participants with COPD according to ATS guidelines. Baseline pre-
bronchodilation FEV1 < 65% predicted and > 0.70 L. Baseline pre-bronchodilation
FEV1/FVC ≤ 70% predicted. Age > 40, 20 pack-year history smoking, day or night
symptoms present on 4 out of last 7 days during run-in period
Exclusion criteria: history of asthma, corticosteroid use in last 6 weeks, abnormal ECG,
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Mahler 2002 (Continued)
oxygen therapy, moderate or severe exacerbation during run-in, significant concurrent
disease
Interventions Run-in: 2 weeks treatment with placebo inhaler and SABA as needed
1. salmeterol 100 µg per day: 50 µg twice daily
2. fluticasone propionate 1000 µg per day: 500 µg twice daily
Inhaler device: Diskus
Co-treatment: Patients were given as-needed albuterol
Outcomes Exacerbations, change in FEV1 from baseline to end of study; morning PEF; quality of
life (CRDQ, CBSQ not stratified by reversibility); dyspnoea (BDI, TDI); symptoms;
use of reliever medication (salbutamol); adverse events
Notes Reversibility defined as an increase of 12% and 200 mL in FEV1 following albuterol
400 µg
Change in FEV1: mean group SE estimated from reversibility stratified SEs, then used
to calculate SD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Endpoint analysis for both predose and
post-dose FEV1 was performed to ensure
that the patients prematurely withdrawing
from the trial did not impact the robust-
ness of the FEV1 results. The endpoint was
defined as the last on-treatment post-base-
line assessment excluding any data from the
discontinuation visit. The appropriateness
of this analysis was supported by evaluat-
ing the data using alternative methods of
handling dropouts, including multiple im-
putation, analysis of only completers, and
recursive regression imputation
Selective reporting (reporting bias) Low risk All collected data reported
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Szafranski 2003
Methods Design: a multi-centre, randomised, double-blind, placebo-controlled, parallel-group
study. Trial durationwas 2week run-in period and 52weeks treatment. The trial included
89 centres in 11 countries from Central & South America, Europe and South Africa
Participants Participants: 399 patients were randomised (formoterol 201; budesonide 198).
Baseline characteristics: mean age 64 years; 78% male; mean predose FEV1 1.0 L;
mean FEV1 predicted 36%, mean reversibility 6% predicted normal
Inclusion criteria: age ≥ 40 years; COPD for ≥ 2 years; smoking history ≥ 10 pack
years; FEV1 ≤ 50% predicted; FEV1/FVC ≤ 70%; Symptom score ≥ 2 during at least
7 days of run-in; use of bronchodilators for reliever medication; ≥ 1 severe COPD
exacerbation within 2-12 months before study entry
Exclusion criteria: history of asthma/rhinitis before age of 40; using beta-blockers;
current respiratory tract disease other than COPD
Interventions Run-in: 2 weeks. Treatment as-needed with short-acting bronchodilators only
1. budesonide 800 µg per day: 2 x 200 µg twice daily
2. formoterol 18 µg per day: 2 x 4.5 µg twice daily
Inhaler device: Turbuhaler
Co-treatment: Only study medication was allowed during the treatment period and
terbutaline 0.5 mg when
needed as reliever medication
Outcomes Number of mild and severe exacerbations; change in post-dose FEV1 as % from baseline;
dyspnoea (MMRC); symptoms; morning and evening PEF; quality of life (SGRQ); use
of reliever medication; adverse events
Notes Classified as ’poorly reversible’ subgroup
Severe exacerbation defined as requirement of oral steroids and/or antibiotics and/or
hospitalisation for respiratory symptoms. Mild exacerbation defined as requirement of
≥ 4 inhalations per day
P values used to calculate pooled SEMs for following outcomes: Symptoms; rescue
medication usage
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
scheme at AstraZeneca, Lund, Sweden. At
each centre, eligible patients received an en-
rolment code and then after run-in, partic-
ipants were allocated the next consecutive
patient number
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk All the Turbuhaler inhalers were identical
to ensure that the patient, pharmacist and
the investigator were blinded to the allo-
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Szafranski 2003 (Continued)
cated treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were relatively large
but evenbetween the inhaled corticosteroid
(budesonide) group (31%) and the long-
acting beta2-agonist (formoterol) group
(32%). An intention-to-treat analysis was
used
Selective reporting (reporting bias) Low risk All collected data reported
Tashkin 2008
Methods Design: a multi-centre, randomised, double-blind, double-dummy, placebo-controlled,
parallel-group study. Trial duration was 2 week run-in, 6 months treatment, and tele-
phone follow-up 4 weeks after the last study visit. The trial included 194 centres in 5
countries (42% US)
Participants Participants: 559 patients were randomised (budesonide 275; formoterol 284)
Baseline characteristics: mean age 63 years; 67% male; mean predose FEV1 1.03 L;
mean predose FEV1 predicted 40%
Inclusion criteria: Current or ex-smokers aged ≥ 40 years; clinical diagnosis of COPD
with symptoms for > 2 years; ≥ 1 COPD exacerbation requiring oral corticosteroids/
antibiotics 1 to 12 months before first clinic visit; use of SABAs as reliever medication;
predose FEV1 ≤ 50%predicted; predose FEV1 /FVC≤ 70%; smoking history≥ 10 pack
years; dyspnoea scale (MMRC) ≥ 2; breathlessness, cough and sputum scale (BCSS)
score ≥ 2 per day for at least half of the 2-week run-in period
Exclusion criteria: history of asthma/rhinitis before 40 years of age; significant/unsta-
ble cardiovascular disorder; clinically significant respiratory tract disorder other than
COPD; homozygous α-1 antitrypsin deficiency; if the patient needed additions or al-
terations to their usual COPD maintenance therapy or an increment in rescue therapy
due to worsening symptoms within 30 days before screening or during the run-in; oral
or ophthalmic non-cardioselective beta-adrenoceptor antagonists, oral corticosteroids,
pregnancy and breast-feeding
Interventions Run-in: 2 weeks. Patients continued ICS mono-therapy if they had previously been re-
ceiving ICS alone or in combination with a LABA, and patients who had previously been
receiving anticholinergic therapies were placed on stable doses of ipratropium bromide.
A short-acting beta2-adrenoceptor agonist was allowed for rescue use
1. budesonide 640 µg per day: 2 x 160 µg twice daily (Turbuhaler)
2. formoterol 18 µg per day: 2 x 4.5 µg twice daily (pMDI)
Co-treatment:
Allowed: Ephedrine-free (or other bronchodilator-free) antitussives andmucolytics, nasal
corticosteroids, stable-dose non-nebulized ipratropium bromide, oral or ophthalmic car-
dioselective beta-adrenoceptor antagonists, study-provided salbutamol (albuterol) as res-
cue medication, medications allowed for exacerbations after randomisation: oral and
parenteral corticosteroids (not depot formulations), acute use of xanthines, increased use
of inhaled beta-adrenoceptor agonists and ipratropium bromide, and nebulized beta-
adrenoceptor agonists and ipratropium bromide
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Tashkin 2008 (Continued)
Disallowed: Long-acting anticholinergics, inhaled LABAs (other than study medication)
, inhaled SABAs (other than salbutamol [albuterol] for rescue), oral beta-adrenocep-
tor agonists, ephedrine-containing medication, leukotriene receptor antagonists and 5-
lipoxygenase inhibitors, xanthine-containing derivatives (except in short-term treatment
of exacerbations), disodium cromoglygates, non-cardioselective beta-adrenoceptor an-
tagonists, ICSs (other than study medication)
Outcomes Pre- and post-dose FEV1; inspiratory capacity; FVC; morning and evening PEF; dys-
pnoea (BCSS); quality of life (SGRQ); exacerbations; use of reliever medication (beta-
agonist); symptoms; adverse events
Notes Exacerbations were defined as respiratory symptoms requiring treatment with a course
of oral steroids and/or hospitalisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomised in bal-
anced blocks according to a computer-gen-
erated randomisation scheme at each site
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk To maintain blinding, patients received
both a pressurized metered-dose inhaler
(pMDI) and a dry powder inhaler (DPI)
containing either active treatment or
placebo, or combinations of active treat-
ment and placebo, as appropriate
Incomplete outcome data (attrition bias)
All outcomes
Low risk The withdrawal rates were 23% in the
inhaled corticosteroid (budesonide) group
and 22% in the long- acting beta2-agonist
(formoterol) group. However the efficacy
analysis set (i.e. intention-to-treat popula-
tion) included all randomised patients who
received at least one dose of study medica-
tion and contributed sufficient data for at
least one co-primary or secondary efficacy
endpoint during the randomised treatment
period
Selective reporting (reporting bias) Low risk All collected data reported
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TORCH 2007
Methods Design: a multi-centre, randomised, double-blind, placebo-controlled, parallel-group
study.
Trial duration was 2 week run-in period and 156 weeks treatment. The trial included
444 centres in 42 countries in North America, Central America and Asia Pacific
Participants Participants: 3093 patients were randomised (salmeterol: 1542; fluticasone 1551)
Baseline characteristics: mean age 65 years; 76% male; mean FEV1 predicted 44%,
mean predose FEV1 1.1 L, mean SGRQ score 50
Inclusion criteria: male/female 40-80 years of age; diagnosis of COPD (ERS); < 10%
reversibility of predicted FEV1; FEV1/FVC ratio < 70%; FEV1< 60% predicted; ≥ 10
pack year smoking history
Exclusion criteria: Asthma or respiratory diseases other than COPD; lung volume
reduction surgery/lung transplant; requirement for > 12 h/day long term oxygen therapy;
long term oral corticosteroid therapy; serious uncontrolled disease likely to interfere with
medication/cause death in next three years
Interventions Run-in: 2 weeks. All maintenance treatment with ICS and LABA ceased, but patients
could continue other medications for COPD
1. salmeterol 100 µg per day: 50 µg twice daily
2. fluticasone 1000 µg per day: 500 µg twice daily
Inhaler device: DPI (Diskus)
Co-treatment: Patients could continue medications for COPD other than corticos-
teroids and inhaled long-acting bronchodilators
Outcomes All cause mortality; frequency of exacerbations; health status (SGRQ); change in post-
dose FEV1 from baseline to end of study; adverse events
Notes Exacerbation defined as symptomatic deterioration requiring treatment with antibiotics,
systematic corticosteroids, hospitalisation or a combination of these
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible patients were randomly assigned to
study treatment in accordancewith the ran-
domisation schedule, which was generated
using the GW computer program Patient
Allocation for Clinical Trials (PACT). Pa-
tients were randomised in permuted blocks
with stratification according to country and
smoking status
Allocation concealment (selection bias) Low risk Medicationwas allocated by the use of three
numbers as follows.
• Each subject who was screened was allo-
cated a subject number. This number was
unique to each subject and was assigned
from a list provided to the site, in chrono-
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TORCH 2007 (Continued)
logical order.
• Each subject who satisfied the randomi-
sation criteria was assigned a unique treat-
ment number from the Interactive Voice
Response (IVR) system which is part of
the System for Central Allocation of Drug
(SCAD). Once a treatment number had
been assigned to a subject, it could not be
assigned to any other subject. Neither the
subject nor the investigator knew to which
treatment arma subject hadbeen allocated.
• At each treatment visit the subject was
providedwith a treatment pack. Every pack
number was unique and corresponded to
the study medication pack which was dis-
pensed to the subject at the visit
A specialist IVR system company, Clin-
Phone, managed this system. At the ran-
domisation visit (Visit 2) the principal
investigator or designee contacted the
IVR system through an automated 24-
hour telephone number; upon providing
their unique personal identification num-
ber (PIN) and answering a series of ques-
tions, the site was provided with the sub-
ject’s treatment number as well as a pack
number
Blinding (performance bias and detection
bias)
All outcomes
Low risk Neither the subject nor the investigator
knew to which treatment arm a subject
had been allocated. At each treatment visit
each subject was issued with a treatment
pack containing DISKUS/ACCUHALER
inhalers. The inhalers contained either of
the four treatments (salmeterol/fluticasone
propionate combination product, fluticas-
one propionate, salmeterol, or placebo) in
accordance with the randomisation sched-
ule. The inhalers were labelled in accor-
dance with all applicable regulatory re-
quirements. Each treatment pack and study
treatment inhaler was labelledwith the pro-
tocol number, storage and dosing instruc-
tions by GW Research and Development
Incomplete outcome data (attrition bias)
All outcomes
Low risk For patients who withdrew from the study
prematurely, all data on exacerbations,
health status, and lung function available
at the time of a patient’s withdrawal from
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the study were included in the analysis. All
efficacy analyses were performed according
to the intention-to-treat principle
Selective reporting (reporting bias) Low risk All collected data reported
TRISTAN 2003
Methods Design: a multi-centre, randomised, double-blind, placebo-controlled, parallel-group
study. Trial duration was 2 week run-in period, 52 weeks treatment, and 2-week follow-
up. The trial included 196 centres in 25 countries
Participants Participants: 746 patients were randomised (salmeterol: 372; fluticasone 374)
Baseline characteristics: mean age 63 years; 70% male; mean reversibility (FEV1%
predicted) 3.7%; mean FEV1 predicted 45%, mean predose FEV1 1.25 L, mean SGRQ
score 49
Inclusion criteria: male/female; poor reversibility < 10% increase of predicted FEV1
30 minutes after inhaling 400 µg salbutamol; FEV1/FVC ratio <70%; baseline FEV1
25 - 75% predicted; ≥10 pack year smoking history, chronic bronchitis; history of
exacerbations (at least 1 in the last year) requiring oral corticosteroids and/or antibiotics.
At least one episode of acute COPD per year in the previous 3 years
Exclusion criteria: respiratory disorders other than COPD, oxygen treatment, systemic
corticosteroids, high doses of inhaled corticosteroids (> 1000 µg daily beclomethasone
dipropionate, budesonide or flunisolide or > 500 µg daily fluticasone) or antibiotics in
the four weeks before the 2 week run-in period
Interventions Run-in: 2 weeks. All maintenance treatment with ICS and LABA ceased
1. salmeterol 100 µg per day: 50 µg twice daily
2. fluticasone propionate 1000 µg per day: 500 µg twice daily
Inhaler device: DPI (Diskus)
Co-treatment: Inhaled salbutamol was used as relief medication throughout the study,
and regular treatment with anticholinergics, mucolytics, and theophylline was allowed.
All non-COPDmedications could be continued if the dose remained constant whenever
possible, and if their use would not be expected to affect lung function
Outcomes Change in pre- and post-dose FEV1 from baseline to end of study; use of reliever med-
ication (salbutamol); symptom scores; exacerbation rate; quality of life (SGRQ); FVC;
adverse events
Notes Exacerbations were defined a priori as a worsening of COPD symptoms that required
treatment with antibiotics, oral corticosteroids, or both
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A randomisation schedule generated by the
patient allocation for clinical trials (PACT)
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TRISTAN 2003 (Continued)
program was used to assign patients to
study treatment groups. Every participat-
ing centre was supplied with a list of pa-
tient numbers (assigned to patients at their
first visit) and a list of treatment numbers.
Patients who satisfied the eligibility criteria
were assigned the next sequential treatment
number from the list
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Study drugs were labelled in a way to en-
sure that both the patient and the investi-
gator were unaware of the allocated treat-
ment. Salmeterol and fluticasone combina-
tion (50/500 µg twice daily), salmeterol (50
µg twice daily), fluticasone (500 µg twice
daily) and placebo were packaged in iden-
tical inhaler devices
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The withdrawal rates were even between
the inhaled corticosteroid (budesonide)
group (29%) and the long-acting beta2-ag-
onist (formoterol) group (32%) and the %
of patients lost to follow-upwere only 2.1%
and 2.2% for the two groups respectively.
However, it was unclear if patients discon-
tinuing the allocated study treatment were
analysed according to an intention-to-treat
principle
Selective reporting (reporting bias) Low risk All collected data reported
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barnes 2005 No ICS and LABA monocomponents
Cazzola 2003 No ICS and LABA monocomponents
Della Cioppa 2001 No ICS and LABA monocomponents
Gosman 2006 No ICS and LABA monocomponents
Jiang 2009 No ICS and LABA monocomponents
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Lyseng-Williamson 2002 Review article
Mittmann 2010 No ICS and LABA monocomponents
Nungtjik 2009 No ICS and LABA monocomponents
Reynolds 2004 Review article
Tzani 2010 No ICS and LABA monocomponents
Worth 2009 No ICS monocomponent
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D A T A A N D A N A L Y S E S
Comparison 1. Inhaled corticosteroids (ICS) versus long-acting beta2-agonists (LABA) by ICS and LABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbation rate ratios 4 4750 Risk Ratio (Fixed, 95% CI) 0.96 [0.89, 1.02]
1.1 Fluticasone versus
Salmeterol
2 3839 Risk Ratio (Fixed, 95% CI) 0.97 [0.91, 1.05]
1.2 Budesonide versus
Formoterol
2 911 Risk Ratio (Fixed, 95% CI) 0.86 [0.73, 1.03]
2 Exacerbations 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Fluticasone versus
Salmeterol
2 688 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.89, 1.67]
3 Hospitalisations due to
exacerbations
1 Risk Ratio (Fixed, 95% CI) Totals not selected
3.1 Fluticasone versus
Salmeterol
1 Risk Ratio (Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Pneumonia adverse event 3 4164 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [1.10, 1.73]
4.1 Fluticasone versus
Salmeterol
1 3093 Odds Ratio (M-H, Fixed, 95% CI) 1.43 [1.13, 1.81]
4.2 Budesonide versus
Formoterol
2 1071 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.36, 1.96]
5 Pneumonia serious adverse event 5 5086 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.48 [1.13, 1.94]
5.1 Fluticasone versus
Salmeterol
4 4527 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.46 [1.12, 1.92]
5.2 Budesonide versus
Formoterol
1 559 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.82 [0.40, 20.16]
6 Pre-dose FEV1 4 1993 Mean Difference (Fixed, 95% CI) -18.99 [-37.46, -0.
52]
6.1 Fluticasone versus
Salmeterol
3 1434 Mean Difference (Fixed, 95% CI) -10.88 [-32.62, 10.
87]
6.2 Budesonide versus
Formoterol
1 559 Mean Difference (Fixed, 95% CI) -40.0 [-73.00, -5.00]
7 Post-dose FEV1 2 Mean Difference (Fixed, 95% CI) Totals not selected
7.1 Fluticasone versus
Salmeterol
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Budesonide versus
Formoterol
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Mild exacerbations 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Fluticasone versus
Salmeterol
2 688 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.74, 3.08]
9 Mortality 7 5997 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.97, 1.42]
9.1 Fluticasone versus
Salmeterol
4 4527 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [1.01, 1.51]
9.2 Budesonide versus
Formoterol
3 1470 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.62 [0.31, 1.22]
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10 Health-related quality of life
SGRQ
3 4398 Mean Difference (Fixed, 95% CI) -0.74 [-1.42, -0.06]
10.1 Fluticasone versus
Salmeterol
2 3839 Mean Difference (Fixed, 95% CI) -0.77 [-1.49, -0.04]
10.2 Budesonide versus
Formoterol
1 559 Mean Difference (Fixed, 95% CI) -0.51 [-2.63, 1.61]
11 Dyspnoea symptom score 0-4 3 1817 Mean Difference (Fixed, 95% CI) 0.03 [-0.02, 0.08]
11.1 Fluticasone versus
Salmeterol
1 746 Mean Difference (Fixed, 95% CI) -0.01 [-0.08, 0.06]
11.2 Budesonide versus
Formoterol
2 1071 Mean Difference (Fixed, 95% CI) 0.07 [-0.00, 0.14]
12 Dyspnoea TDI 2 Mean Difference (Fixed, 95% CI) Subtotals only
12.1 Fluticasone versus
Salmeterol
2 688 Mean Difference (Fixed, 95% CI) 0.26 [-0.21, 0.74]
13 Symptoms 3 1470 Mean Difference (Random, 95% CI) 0.22 [-0.03, 0.47]
13.1 Budesonide versus
Formoterol
3 1470 Mean Difference (Random, 95% CI) 0.22 [-0.03, 0.47]
14 Adverse events 5 5089 Odds Ratio (M-H, Fixed, 95% CI) 1.12 [0.96, 1.30]
14.1 Fluticasone versus
Salmeterol
4 4530 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.96, 1.35]
14.2 Budesonide versus
Formoterol
1 559 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.74, 1.44]
15 Serious adverse events (non-
fatal)
6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Budesonide versus
Formoterol number of SAEs
3 1470 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.77, 1.31]
15.2 Fluticasone versus
Salmeterol number of patients
with 1 or more SAEs
3 1436 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.60, 2.28]
16 Withdrawals 7 5961 Odds Ratio (M-H, Fixed, 95% CI) 1.02 [0.92, 1.14]
16.1 Fluticasone versus
Salmeterol
4 4491 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.92, 1.18]
16.2 Budesonide versus
Formoterol
3 1470 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.76, 1.20]
Comparison 2. Inhaled corticosteroids versus long-acting beta2-agonists by length of study
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbation rate ratios 4 4750 Risk Ratio (Fixed, 95% CI) 0.96 [0.89, 1.02]
1.1 up to 1 year 3 1657 Risk Ratio (Fixed, 95% CI) 0.94 [0.84, 1.05]
1.2 longer than 1 year 1 3093 Risk Ratio (Fixed, 95% CI) 0.96 [0.89, 1.05]
2 Pneumonia serious adverse event 6 5560 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.42 [1.10, 1.85]
2.1 up to 1 year 5 2505 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.11 [0.58, 2.10]
2.2 longer than 1 year 1 3055 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.50 [1.12, 1.99]
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A D D I T I O N A L T A B L E S
Table 1. Excluded data
Calverley 2003 Hanania 2003 Mahler 2002 Szafranski 2003 Tashkin 2008 TRISTAN 2003
Exacerbations X
Pre-dose FEV1 X X
Post-dose FEV1 X X X
PEF X X X X X
Dyspnoea X
Symptom X
Rescue medica-
tion
X
WH A T ’ S N E W
Last assessed as up-to-date: 3 August 2011.
Date Event Description
11 April 2013 Amended NIHR acknowledgement added
H I S T O R Y
Protocol first published: Issue 2, 2008
Review first published: Issue 10, 2011
Date Event Description
4 November 2011 New citation required but conclusions have not
changed
Author byline amended
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Post-bronchodilator FEV1 was added as an outcome at the suggestion of a peer reviewer.
In the protocol we planned to assess study quality according towhether studiesmet the following pre-specified quality criteria (Handbook
2005):
I) adequacy of the randomisation procedure;
ii) demographic balance of study participants at baseline;
iii) adequacy of blinding procedures for concealing treatment allocation;
iv) adequacy of the reporting and handling of participants who withdrew from treatment.
By the time the review was written the guidelines for assessing study quality had been updated (Higgins 2008). We assessed the risk
of bias for all included studies according to recommendations outlined in The Handbook for Systematic Reviews of Interventions
(Higgins 2008) for the following items:
1. allocation sequence generation;
2. concealment of allocation;
3. blinding of participants and investigators;
4. incomplete outcome data;
5. selective outcome reporting.
We graded each potential source of bias as low, high or unclear risk of bias.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage]; Adrenergic beta-2 Receptor Agonists [∗administration & dosage]; Albuterol
[administration & dosage; analogs & derivatives]; Androstadienes [administration &dosage]; Bronchodilator Agents [administration &
dosage]; Budesonide [administration & dosage]; Ethanolamines [administration & dosage]; Pulmonary Disease, Chronic Obstructive
[∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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